Lipocine (LPCN) Misses Q1 EPS by 54c May 7, 2026 06:18PM
H.C. Wainwright Downgrades Lipocine Inc (LPCN) to Neutral Apr 6, 2026 06:07AM
Lipocine's postpartum depression drug fails primary endpoint in phase 3 trial Apr 2, 2026 08:02AM
Lipocine Inc (LPCN) PT Raised to $15 at H.C. Wainwright Jan 21, 2026 07:07AM
Lipocine Inc (LPCN) PT Lowered to $7 at H.C. Wainwright Nov 13, 2025 06:44AM


Aug 21, 2025 06:41AM H.C. Wainwright Reiterates Buy Rating on Lipocine Inc (LPCN)
Aug 5, 2025 09:32AM Lipocine (LPCN) Misses Q2 EPS by 41c
Jul 11, 2025 06:39AM H.C. Wainwright Reiterates Buy Rating on Lipocine Inc (LPCN)
Jun 30, 2025 06:53AM H.C. Wainwright Reiterates Buy Rating on Lipocine Inc (LPCN)
Jun 26, 2025 08:04AM Lipocine (LPCN) Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression
Jun 10, 2025 06:41AM H.C. Wainwright Reiterates Buy Rating on Lipocine Inc (LPCN)
Jun 9, 2025 08:02AM Lipocine (LPCN) Files New Drug Submission for TLANDO in Canada
May 6, 2025 08:07AM Lipocine (LPCN) Announces License and Supply Agreement for TLANDO in Brazil
Feb 6, 2025 08:03AM Lipocine (LPCN) Receives Updated Regulatory Guidance on LPCN 1154
Dec 17, 2024 08:01AM Lipocine (LPCN) Granted FDA Fast Track Designation for LPCN 1148
Oct 31, 2024 08:01AM Lipocine (LPCN) Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO in South Korea
Oct 10, 2024 08:02AM Lipocine (LPCN) Announces Positive Oral Brexanolone Quantitative EEG Results
Oct 8, 2024 08:02AM Lipocine (LPCN) Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO in the GCC Countries
Jun 25, 2024 08:03AM Lipocine (LPCN) Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone